You are here

  • Home
  • Archive
  • Volume 30, Issue Suppl 1
  • 4CPS-219 Agamenon-seom model for the prediction of survival in patients with HER2-positive advanced oesophagogastric adenocarcinoma receiving trastuzumab-based first-line treatment

Article metrics

Article menu

Download PDFPDF

Section 4: Clinical pharmacy services
4CPS-219 Agamenon-seom model for the prediction of survival in patients with HER2-positive advanced oesophagogastric adenocarcinoma receiving trastuzumab-based first-line treatment
Free

 

Online download statistics by month:

Online download statistics by month: March 2023 to September 2024

AbstractFullPdf
Mar 20232502
Apr 20232806
May 20232201
Jun 20231201
Jul 20231805
Aug 20231103
Sep 2023606
Oct 20231300
Nov 2023902
Dec 20232104
Jan 2024401
Feb 20241101
Mar 20242007
Apr 2024500
May 20242500
Jun 20241500
Jul 2024705
Aug 2024804
Sep 20241102
Total271050